FeesSafety
Pluang+

Cap expands onchain credit marketplace to finance film production without tokenizing assets

Market News
04 Nov 2026, 23:00 WIB
Not Specified
View Source
Bullish
Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports specialized credit markets without needing to tokenize real-world assets. Cap's approach separates loan collateral from repayment guarantees, allowing underwriters to evaluate offchain credit risk and back loans with onchain collateral. This expansion aims to bring more traditional credit markets onto blockchain infrastructure, serving borrowers outside the crypto ecosystem and enabling new credit opportunities through specialized underwriting expertise.

Cap's expansion into film and media financing is the subject, with Pluang's Financials sector data providing market context. As of Nov 04, 2026 22:12 WIB, out of 142 priced Financials-sector US stocks tradable on Pluang, 119 rose and 23 fell. Notable movers include RKT at USD 14.81 with a 7.28% increase and a typical hold time of 2 days, AFRM at USD 77.19 up 7.25%, and LMND at USD 44.33 rising 7.23%.

More News

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...

Market News
Bearish
16 minutes ago
Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...

Company Fundamentals
Bullish
16 minutes ago
ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...

Market News
Bullish
16 minutes ago
New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...

Others
Bullish
16 minutes ago
Global AI accelerator market to hit $443B by 2030, driven by generative AI and edge computing growth.

Global AI accelerator market to hit $443B by 2030, driven by generative AI and edge computing growth.

The global AI accelerator market is projected to grow from $151 billion in 2025 to $443 billion by 2030, with a compound annual growth rate of about 24%. This expansion is fueled by the rise of generative AI, large language models, and increased inve...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App